Human IgG/FcγR Interactions Are Modulated by Streptococcal IgG Glycan Hydrolysis by Allhorn, Maria et al.
Human IgG/FccR Interactions Are Modulated by
Streptococcal IgG Glycan Hydrolysis
Maria Allhorn
1*, Anders I. Olin
1, Falk Nimmerjahn
2, Mattias Collin
1
1Division of Infection Medicine, Department of Clinical Sciences, Lund University, Lund, Sweden, 2Experimental Immunology and Immunotherapy,
Nikolaus-Fiebiger-Center for Molecular Medicine, Erlangen, Germany
Background. The human pathogen Streptococcus pyogenes produces an endoglycosidase, EndoS that hydrolyzes the
chitobiose core of the asparagine-linked glycan on the heavy chain of human IgG. IgG-binding to Fc gamma receptors (FccR)
on leukocytes triggers effector functions including phagocytosis, oxidative burst and the release of inflammatory mediators.
The interactions between FccR and the Fc domain of IgG depend on the IgG glycosylation state. Methodology/Principal
Findings. Here we show for the first time that EndoS hydrolyzes the heavy chain glycan of all four human IgG subclasses
(IgG1-4), in purified form and in a plasma environment. An inactive form of EndoS, obtained by site-directed mutagenesis,
binds IgG with high affinity, in contrast to wild type EndoS that only transiently interacts with IgG, as shown by Slot-blotting
and surface plasmon resonance technology. Furthermore, EndoS hydrolysis of the IgG glycan influences the binding of IgG to
immobilized soluble FccR and to an erythroleukemic cell line, K562, expressing FccRIIa. Incubation of whole blood with EndoS
results in a dramatic decrease of IgG binding to activated monocytes as analyzed by flow cytometry. Moreover, the IgG bound
to K562 cells dissociates when cells are treated with EndoS. Likewise, IgG bound to immobilized FccRIIa and subsequently
treated with EndoS, dissociates from the receptor as analyzed by surface plasmon resonance and Western blot. Conclusions/
Significance. We provide novel information about bacterial enzymatic modulation of the IgG/FccR interaction that emphasizes
the importance of glycosylation for antibody effector functions. Moreover, EndoS could be used as a biochemical tool for
specific IgG N-glycan hydrolysis and IgG purification/detection, or as a potential immunosuppressing agent for treatment of
antibody-mediated pathological processes.
Citation: Allhorn M, Olin AI, Nimmerjahn F, Collin M (2008) Human IgG/FccR Interactions Are Modulated by Streptococcal IgG Glycan Hydrolysis. PLoS
ONE 3(1): e1413. doi:10.1371/journal.pone.0001413
INTRODUCTION
The immunoglobulin G (IgG) class of antibodies plays an important
role in the adaptive immune defense of the human host against
pathogens. IgG consists of two identical heavy chains and two
identical light chains, which in turn are composed of variable and
constant domains. Papain treatment of the IgG molecule generates
two separate monovalent Fab fragments recognizing antigens and
an intact Fc fragment, a recognition site for host receptors and a site
of interaction with a number of effector molecules, including the
classical complement pathway starting with factor C1q [1,2]. IgG is
a glycoprotein containing a conserved complex carbohydrate
structure attached to the asparagine 297 residue in the CH2
domain of each IgG Fc part. It consists of a biantennary core of N-
acetylglucosamine and mannose with added terminal and branch-
ing carbohydrate residues such as N-acetylglucosamine, fucose,
sialic acid, and galactose (Fig. 1A) [3]. The presence of this
carbohydrate is crucial for proper antibody structure and for
interactions with cellular immunoglobulin G Fcc receptors (FccRs)
and the complement system [1,4]. Altered glycosylationof IgG have
been associated with autoimmune disorders like rheumatoid
arthritis (RA), systemic lupus erythematosus (SLE) and Crohns
disease [5–7]. Several forms of autoimmune vasculitis show a
differentiating glycosylation with decreased Fc galactosylation and
sialylation [8–12]. Additionally, it has been suggested that sialylated
IgG in vivo switch from its anti-inflammatory activity with
subsequent reduced antibody effector activity, to a pro-inflamma-
tory/toxic activity upon decreased Fc sialylation [13]. IgGs,
classified into four subclasses, IgG1, IgG2, IgG3 and IgG4, are
described to interact with different types of FccRs giving different
activation profiles [14,15].
FccRs provide a linkage between the humoral and cellular
immune responses. Phagocytic cells express members of three
classes of IgG-Fc receptors, FccRI, FccRII and FccRIII, charac-
terized by structural and functional homology and by the specific
recognition site on the CH2 region of IgG [1,16,17]. Binding of
pathogen-IgG complexes to FccRs mediates an essential response
from the host against pathogens by initiating a cascade of signals
causing antibody-dependent-cellular-cytotoxicity (ADCC), comple-
ment-dependent-cellular-cytotoxicity (CDCC), endocytosis, phago-
cytosis, oxidative burst, the release of inflammatory mediators, etc.
[2,18]. Complexed IgG-FccR can besides activation of the C1q
component of complement also activate other ligands e.g. mannan
binding lectin (MBL), the neonatal receptor FcRn, the mannose
receptor (MR), etc. [2,4]. FccRs may be expressed constitutively on
haematopoietic cells and may also be induced or up-regulated by
cytokines and other agents. FccRs are responsible for balancing
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(FccRIIb) of the immune system with the ability of both activating
and inhibiting the IgG mediated effector stimulation [1,19].
Streptococcus pyogenes is one of the most common human
pathogens causing pharyngitis, scarlatina and more severe
infections like necrotizing fasciitis and sepsis [20,21]. Like other
bacteria it expresses several virulence factors and uses several
immune evasion strategies to successfully invade its host [22–25].
The recently discovered enzyme Endoglycosidase S (EndoS) is
secreted by Streptococcus pyogenes and has a specific endoglycosidase
activity on native IgG by hydrolyzing the conserved asparagine-
linked glycans on the heavy chains of IgG (Fig. 1A) [24,26]. This
108 kDa-enzyme is encoded by the gene ndoS that is highly
conserved and is present in virtually all examinated isolates. EndoS
is the first known bacterial enzyme with a unique specificity for
native IgG [24]. This is in contrast to other related endoglyco-
sidases as EndoF1-3 from Elisabethkingia meningoseptica (previously
Flavobacterium meningosepticum), which show enhanced hydrolytic
activities on the denaturated forms of basically any glycoproteins
with the appropriate N-linked glycan, or EndoE from Enterococcus
faecalis that in addition to activity on the glycan of native IgG also
hydrolyzes high-mannose glycans on other denatureted glycopro-
teins [27,28]. EndoS is N-terminally processed by the cysteine
proteinase SpeB that could be of importance in regulating EndoS
activity [29]. Furthermore, the molecular requirements for EndoS
glycosidase activity have recently been elucidated revealing the
importance of glutamic acid 235 (Glu-235) and tryptophans [29].
EndoS activity affects the functionality of opsonizing IgG by
decreased binding to Fc-receptors on a monocyte-like cell line and
impaired classical complement activation in vitro [26].
In the present study we elucidated the effect(s) of EndoS on IgG
subclasses and IgG-FccR interactions. The results revealed that
EndoS hydrolyses the heavy chain of all four human IgG
subclasses (IgG1–4), both soluble and in a plasma environment.
Additionally, we found that EndoS hydrolysis of the IgG glycan
dramatically influences the binding of IgG to soluble, immobilized
FccRIIa and FccRIIb as well as to FccR-expressing cells.
Moreover, IgG pre-bound to these cells dissociates due to
treatment of cells with EndoS. Furthermore, an inactive form of
EndoS generated by site-directed mutagenesis binds with high
affinity to IgG1–4, while the active form only transiently interacts
with its substrates. These results provide novel information about
the mechanisms behind enzymatic modulation of the host immune
defense by bacteria, provide novel information about the
molecular interactions between an IgG glycan-hydrolyzing
enzyme and IgG, and emphasize the importance of IgG
glycosylation for correct antibody effector functions.
RESULTS
EndoS has glycosidase activity on all four IgG
subclasses
It has previously been shown that EndoS hydrolyzes the chitobiose
core of the conserved N-linked glycan on the c-chain of human
Figure 1. EndoS has glycosidase activity on all four human IgG subclasses. Panel A. Glycan structure of human IgG. Glycan on the c2chains of IgG
attached to aspargine 297. GlcNAc, N-acetylglucosamine; Fuc, fucose; Man, mannose; Gal, galactose; NeuAc, sialic acid. Cleavage site for EndoS and
recognation site for Lens culinaris agglutinin lectin (LCA) are indicated. Panel B. Purified IgG 1–4 incubated with EndoS and analyzed by SDS-PAGE
and stained. Panel C. IgG 1–4 incubated with EndoS and analyzed using LCA lectin blot.
doi:10.1371/journal.pone.0001413.g001
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whether EndoS has activity on all four subclasses of human IgG
(IgG1–4). Purified recombinant EndoS was incubated with purified
human IgG1–4. SDS-PAGE analysis revealed that EndoS-treated
IgG of all subclasses migrated at an apparent molecular weight of
approximately 3 kDa lower than untreated IgG (Fig. 1B), which is
consistent with hydrolysis of the chitobiose core of the IgG glycan.
To confirm glycan hydrolysis, samples were also analyzed by lectin
blot using a Lens culinaris agglutinin (LCA) lectin recognizing a-
linked mannose residues (Fig. 1A). Lectin blot analysis of the
samples revealed that all IgG subclasses lose the reactivity withLCA
after incubation with EndoS consistent with complete or nearly
complete hydrolysis of the glycan (Fig. 1C). Additionally, the
glycosidase activity of EndoS on IgG1–4 in a plasma environment
was investigated. In this experiment human plasma was incubated
withpurified EndoSorbuffer,followed byaffinitypurificationofthe
IgG fraction. These fractions were subsequently subjected to a LCA
ELISA using immobilized monoclonal antibodies against IgG1–4 to
capture IgG. This revealed that all four IgG subclasses reacted with
lectin when plasma was incubated with buffer, indicating presence
of the glycan (data notshown).In contrast, when plasmawastreated
with EndoS, a dramatically reduced IgG1–4 reactivity with LCA
lectin was observed. IgG1 was hydrolyzed to 87611%, IgG2 was
hydrolyzed to 81613%, IgG3 was hydrolyzed to 74623%, and
IgG4 was hydrolyzed to 7263% (Fig. 2). Taken together, these
results clearly show that EndoS has the ability to hydrolyze human
IgG of all subclasses, in purified form as well as in whole plasma.
The inactive form of EndoS binds IgG
We have previously partly elucidated the molecular requirements
for EndoS hydrolysis of IgG. Site directed mutagenesis of glutamic
acid 235 to glutamine (EndoS(E235Q)) at the proposed orifice of
the catalytic tunnel abolishes enzymatic activity. In addition,
chemical blocking of tryptophanes revealed that these amino acid
residues are important for activity [29]. To further investigate the
physical interaction between enzyme and substrate, the binding of
EndoS and EndoS(E235Q) to immobilized polyclonal IgG and
IgG1–4 subclasses was studied using slot-binding experiments with
immobilized IgG probed with EndoS and EndoS(E235Q).
Purified, soluble IgG subclasses 1–4, each immobilized onto a
nitrocellulose membrane, were probed with EndoS and Endo-
S(E235Q) followed by incubation with antibodies against EndoS.
This experiment revealed a strong binding of EndoS(E235Q) to
polyclonal IgG, IgG1 and IgG2, and a weaker association to IgG3
and IgG4, while only very weak interactions between active EndoS
and all subclasses could be seen (Fig. 3A). To calculate the affinity
constants between EndoS and immobilized IgG1–4, surface
plasmon resonance technology was used. Similarly to slot-binding
results, this showed that EndoS(E235Q) binds all IgG subclasses
with high affinity, while there is no detectable binding of EndoS to
IgG. (Fig. 3B, Table 1). The kinetic parameters of EndoS (E235Q)
binding to immobilized IgG subclasses were of similar character
and the strongest interaction was demonstrated between IgG1 and
EndoS(E235Q) with a binding affinity constant (KD) of 0.42 mM.
No binding of either EndoS or EndoS(E235Q) to IgG1–4
subclasses, which were hydrolysed by EndoS before immobiliza-
tion, was detected. These findings indicate that the intact IgG
glycan is necessary for the interaction between EndoS and IgG.
Furthermore, the experiments comparing the interactions between
EndoS, EndoS(E235Q) and IgG indicates that EndoS binds IgG
with a high affinity, but the active enzyme is instantly released
after glycan hydrolysis in a ‘‘touch and go’’ manner.
EndoS influences the binding of IgG1–4 to FccRs
Since the nature of the interactions between FccRs and the Fc
domain of IgG is highly dependent on the IgG glycosylation state
[1,3,4] we explored the effects of EndoS activity on IgG
interactions with FccRs. Thus, in an ELISA experiment the
soluble FccRIIa, FccRIIb and FccRIIIa were immobilized and
probed with purified IgG1–4 subclasses. In line with other
observations it was here seen that FccRIIa and FccRIIb binds
IgG1 [14]. This binding was nearly abolished after treatment of
IgG1 with EndoS. The binding of the other IgG subclasses to these
receptors was weak and was even more reduced after treatment
with EndoS. In general, ELISA studies revealed the IgG subclass
binding affinity pattern IgG1.IgG3.IgG4.IgG2 for FccRIIa
and IgG1.IgG4.IgG3.IgG2 for FccRIIb (Fig. 4A). Further-
more, we observed that the EndoS hydrolysed IgG2 had a
different outcome regarding the binding to FccRIIa/FccRIIb with
more extensive binding ability, compared to the untreated IgG2.
FccRIIIa was negative in binding of all IgG subclasses (data not
shown). The interaction between IgG1–4, with or without EndoS
treatment, with FccRs was further analyzed by surface plasmon
resonance. Each IgG subclass was tested for binding to a surface
with an immobilized FccRIIa, FccRIIb or FccRIIIa. Consistent
with the ELISA data, the results showed that IgG1 had the
strongest affinity for both FccRIIa and FccRIIb with similar
binding affinity constants, 97 nM and 170 nM respectively (Fig. 4B,
Table 2). In agreement with our previous findings, no binding of
IgG1 to these receptors was detectable when EndoS treated IgG1
was used. There was no detectable interaction between FccRIIa/
FccRIIb and IgG2 or IgG3, or between IgG4 and FccRIIa
(Table 2). No binding of soluble IgG1–4 subclasses to immobilized
FcRIIIa could be detected. These results indicate that EndoS
hydrolysis dramatically decreases IgG’s affinity for FccRs.
EndoS decreases IgG binding to blood cells
Based on results from ELISA and surface plasmon resonance, we
continued to analyze the effect(s) of EndoS glycosidase activity on
the interaction between FccRs and IgG. For this purpose we used
Figure 2. Hydrolysis of human IgG-subclasses by EndoS in plasma
environment. Human plasma treated with EndoS or PBS and followed
by IgG glycan hydrolysis detection using LCA lectin ELISA of the purified
IgG fraction. The results are presented as percent hydrolysis of each
subclass compared to signals from untreated plasma. Means and
standard deviations, indicated with error bars, were calculated from
three independed experiments using blood from three different donors.
doi:10.1371/journal.pone.0001413.g002
EndoS Disrupts IgG/FccR
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[14,30]. Since soluble FccRI was not available to us, we also
investigated human monocytes that predominantly bind IgG
through this receptor [14]. Thus, IgG was purified from plasma
treated with EndoS or PBS, labeled with
125I and incubated with
the K562 cells. The radioactivity of the cell pellets was measured.
This revealed significantly decreased binding of radioactive IgG,
originally purified from plasma treated with EndoS, to K562 cells
(Fig. 5A). In a control experiment, the specific IgG binding to these
cells was calculated by addition of cold human IgG, which
inhibited the binding of radioactive IgG to 93% (data not shown).
A strong binding of IgG to K562 cells after incubation of cells with
human plasma was confirmed by Western blot and the reactivity
of cell lysates with antibodies against human IgG. In contrast,
there was a clear decrease in binding of IgG to K562 cells
Figure 3. EndoS(E235Q) binds to all IgG-subclasses. Panel A. Slot-blot representing the binding of EndoS and EndoS (E235Q) to each IgG subclass
immobilized onto a nitrocellulose membrane in amounts: 3, 1.5 and 0.75 mg. The binding was detected using antiserum against EndoS. Panel B.
Binding of EndoS (E235Q) to immobilized IgG-classes using BIAcore technology. The selected plot shows EndoS (E235Q) binding to IgG1 using
hydrolysed IgG1 as a reference (bulk changes subtracted).
doi:10.1371/journal.pone.0001413.g003
Table 1. Kinetic constants of EndoS binding to immobilized
human IgG1–IgG4.
......................................................................
EndoS (E235Q) EndoS (E235Q) EndoS (E235Q) EndoS
ka (610
4/M/s) kd (610
23/s) KD (610
27M)
IgG1 4.2 17.6 4.2 nb
a
IgG2 1.2 2.5 2.1 nb
IgG3 10.7 8.9 0.83 nb
IgG4 1.5 2.0 1.4 nb
IgG1–4
b nb nb nb nb
anb=no binding
bIgG1–4 hydrolyzed by EndoS
doi:10.1371/journal.pone.0001413.t001
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PLoS ONE | www.plosone.org 4 January 2008 | Issue 1 | e1413Figure 4. EndoS treatment of IgG subclasses inhibits binding of IgG to FccRII. Panel A. Binding of purified IgG subclasses, with or without EndoS
treatment, to FccRIIa and FccRIIb immobilized to a microtitter plate. HRP-labeled protein G was used for detection of bound IgG subclasses. (2)
indicates intact IgG and (+) EndoS hydrolysed IgG. Means, standard deviations (indicated with error bars), and p values (calculated using Student’s t-
test) were determined from three separate experiments. Panel B. Binding of IgG subclasses to immobilized receptors as visualized using BIAcore
surface plasmon resonance. Plot shows a typical sensorgram, here the IgG1 binding to FccRIIa. An empty flow cell is used as reference (subtracted).
doi:10.1371/journal.pone.0001413.g004
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the binding of
125I-IgG to monocytes as analyzed by SDS-PAGE
was totally inhibited when IgG was treated with EndoS (Fig. 6A).
To further analyze EndoS’ influence on the interaction between
FccRs on monocytes and IgG, flow cytometry analysis of whole
blood was performed. Human blood was pre-incubated with
EndoS before addition of the leukocyte activator fMLP.
Monocytes were gated based on forward and side scatter and
the reactivity of monocytes with monoclonal anti-human IgG
was evaluated. The result revealed that 87% of monocytes
were positive for IgG binding, while only 43% of monocytes
in blood incubated with EndoS were positive (Fig. 6B). These
results indicate that EndoS-hydrolyzed IgG is significantly reduced
in its binding capacity to human cells expressing different sets of
FccRs.
IgG dissociates from FccRIIa upon treatment with
EndoS
Our experiments this far have revealed that EndoS hydrolysis of
IgG inhibits binding to FccRs on cells and surfaces, but it
remained unclear if EndoS has activity on IgG already bound to
FccRs and if such activity could release the IgG bound to FccRs.
Therefore, we investigated the effects of EndoS on IgG bound to
K562 cells that had been exposed to human plasma and
subsequently treated with EndoS. The cell lysates were analyzed
by SDS-PAGE and Western blot using an antibody against human
IgG. There was a significant binding of IgG to K562 cells as
judged by the results presented in figure 7A. Interestingly, no IgG-
band was visible on a blot when cells were treated with EndoS,
suggesting a total IgG dissociation from the cells (Fig. 7A). A
control experiment, using EndoS(E235Q), revealed an IgG signal
on the surface of K562 cells comparable to the untreated cells.
These results strongly suggest that IgG dissociates from the cell
surface due to N-glycan hydrolysis of IgG by EndoS. Similarly, the
effect of EndoS on IgG bound to monocytes was analyzed. This
showed that most of the monocyte-bound IgG dissociated from
cells due to the treatment with EndoS as compared to untreated
cells (Fig. 7B). As expected, monocytes treated with EndoS, in
contrast to control cells, showed no reaction with the LCA lectin,
indicating that the minute amounts of IgG remaining on the cells
as detected in the IgG blot had most likely been hydrolyzed by
EndoS (Fig. 7B). The results demonstrated above were further
confirmed by surface plasmon resonance experiments. Soluble
IgG1 and FccRII receptor were chosen because of our earlier
observation that IgG1 is the strongest binder of FccRII. After
binding of IgG1 to pre-immobilized FccRIIa and reaching a
steady-state dissociation phase, the IgG1 injection was aborted
and replaced by EndoS injection or running buffer. This revealed
that EndoS injection causes the dissociation of IgG1 from
immobilized FccRIIa receptor while the IgG1 dissociation from
FccRIIa was unaffected when adding running buffer (Fig. 7C).
Taken together, these results clearly demonstrate that EndoS by
IgG glycan hydrolysis can release IgG bound to FccRs on cells and
surfaces.
Table 2. Kinetic constants of IgG1–IgG4 binding to different Fc-receptors.
..................................................................................................................................................
FccRIIa FccRIIa FccRIIa FccRIIb FccRIIb FccRIIb FccRIIIa
ka (610
4/M/s) kd (610
23/s) KD (610
27M) ka (610
4/M/s) kd (610
23/s) KD(610
27 M)
IgG1 3.5 3.4 0.97 2.6 4.3 1.7 nb
a
IgG2 nb nb nb nb nb nb nb
IgG3 nb nb nb nb nb nb nb
IgG4 nb nb nb 3.4 6.9 2.0 nb
IgG1–4
b nb nb nb nb nb nb nb
anb=no binding
bIgG1–4 hydrolyzed by EndoS
doi:10.1371/journal.pone.0001413.t002
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Figure 5. EndoS treated IgG does not bind to FccRIIa on K562 cells.
Panel A. The relative binding of radioactive IgG, With or without EndoS
treatment, to K562 cells. The cells were incubated with
125iodine-
labelled IgG (intact or EndoS-treated). The radioactivity of the washed
cell pellets was detected. The binding of
125I- IgG (intact) to K562 cells,
presented here as 100%, represents a specific IgG binding to K562 cells
that could be inhibited by addition of cold IgG. Means, standard
deviations (indicated with error bars), and p values (calculated using
Student’s t-test) were determined from three separate experiments.
Panel B. K562 cells were incubated with human plasma treated with
EndoS or PBS. The cells were resuspended in lysis buffer and analyzed
by SDS-PAGE and Western blot using antiserum against human IgG.
doi:10.1371/journal.pone.0001413.g005
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In the present study we attempted to elucidate the physical
interaction between EndoS and IgG and the physiological
relevance of EndoS IgG N-glycan hydrolyzing activity for IgG-
FccR interactions. We present for the first time that EndoS
specifically acts as an endoglycosidase on all human IgG
subclasses, both in purified form and in a plasma environment.
As expected, there is a physical interaction between the enzyme
and all IgG subclasses, that we successfully demonstrated using an
enzymatically inactive, mutated form of EndoS. In this study we
could not separately investigate the EndoS effects on the isolated
binding of IgG to FccRI. However, we observed that EndoS-
hydrolyzed IgG did not bind to monocytes, and that there was a
nearly complete dissociation of IgG from monocytes upon
hydrolysis by EndoS. Since monocytes express FccRI and this
receptor has the highest affinity for IgG, we conclude that EndoS
influences IgG binding even to FccRI because the effects of EndoS
observed must be predominantly due to involvement of FccRI.
EndoS seems to have an effect on both isotypes of FccRII
receptors, thus influencing both activating and inhibiting IgG
mediated effector stimulation. Interestingly, IgG2 treated with
EndoS, in opposite to what was observed for the other subclasses
of IgG, showed increased binding to FccRIIb, and slightly also to
FccRIIa, immobilized to microtiter plate. One possible explana-
tion for this could be aggregation of IgG2 upon hydrolysis by
EndoS leading to increased binding to FccRs. However, no
binding of IgG2 to FccRs was detected using surface plasmon
resonance which is in agreement with earlier publications [14].
This could be explained by the constant flow of IgG2 over the
immobilized receptors in the case of surface plasmon resonance, in
contrast to ELISA where IgG2 is allowed to aggregate and interact
with the receptor.
The activity of EndoS on IgG has obvious benefits for S. pyogenes
expressing this enzyme with potential modulation and/or evasion
of an IgG-mediated response against the bacteria. We have
previously demonstrated that EndoS treatment of human
Figure 6. EndoS treated IgG does not bind to monocytes. Panel A. Monocytes were incubated with
125iodine-labelled IgG (intact or EndoS-treated).
After incubation for 30 minutes at room temperature, the proteins from cell lysates, 10 mg total protein, were separated by 10% SDS-PAGE. The gel
was dried and analyzed by phosphorimaging. Panel B. Flow cytometry analysis showing the decreased binding of IgG to activated monocytes in
blood treated with EndoS. Human blood was treated with EndoS before addition of leukocyte activator fMLP. The IgG binding to monocytes was
detected using mouse anti-human IgG and FITC-labelled goat anti-mouse IgG as a secondary antibody.
doi:10.1371/journal.pone.0001413.g006
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PLoS ONE | www.plosone.org 7 January 2008 | Issue 1 | e1413Figure 7. Dissociation of IgG from FccRII upon treatment with EndoS. Panel A. IgG bound to K562 cells dissociates from FccRIIa upon incubation
with EndoS but not with EndoS(E235Q). K562 cells were incubated with plasma and subsequently with EndoS, EndoS(E235Q) or PBS. Cell lysates,
10 mg total protein, were analysed for IgG by SDS-PAGE and blot using antiserum against human IgG. Panel B. IgG bound to monocytes dissociates
from FccRs after treatment with EndoS. Monocytes were incubated with plasma and later with EndoS or PBS. Resuspended cell pellets were analyzed
for IgG by blot using antiserum against human IgG. The glycan of IgG was detected by blot and reactivity with LCA lectin. Panel C. A BIAcore setup
showing EndoS affecting the IgG1 dissociation from an immobilized receptor FccRIIa. In two parallel experiments, the injection of EndoS (black curve)
is compared to the injection of buffer (broken line) at the same time-point during the dissociation phase of the IgG1- FccRIIa interaction.
doi:10.1371/journal.pone.0001413.g007
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M protein significantly enhances the bacterial survival in blood
[26]. Therefore, in the context of an intact infecting S. pyogenes,
EndoS is a potentially harmful molecule to the human host that
contributes to the bacterial virulence. In contrast to this, the
purified form of EndoS has substantial potential as a biotechno-
logical tool and/or a therapeutical agent that could be beneficial
for future experimental science and possibly also health care.
Our results reveal that EndoS possesses a capacity to inhibit the
IgG binding to FccRs and detach IgG bound to FccRs on cell
surfaces. We have recently been able to show that pre-treatment of
arthritogenic antibodies abrogates development of arthritis in a
mouse model of collagen-induced arthritis [31]. This suggests that
EndoS may have potential for being further developed as a
therapeutical agent in other antibody-mediated autoimmune
disorders.
We suggest two principally different biotechnological uses of
EndoS, one based on the IgG-glycan hydrolyzing activity of the
wild-type enzyme, and the other based on the high affinity IgG-
binding of EndoS(E235Q). The active enzyme could be used for in
vitro treatment of whole blood or purified blood cells in order to
remove IgG already bound to various FccRs on these cells. This
could facilitate the analysis of effects of specific IgG preparations
added to the cells, regarding receptor binding and cellular
activation, without the interference of pre-bound IgG. The
inactive form of EndoS (EndoS(E235Q)) has a great potential as
a specific IgG purification and detection tool. In this study we have
demonstrated that EndoS(E235Q) interacts equally well with all
subclasses of IgG. This is comparable to what can be seen for
protein G, one of the major molecules currently used for IgG
preparation and detection [32], but advantageous compared to
protein A that does not bind IgG3 [33]. Protein A also binds IgM
and IgA to a certain extent. We have previously shown that there
is no interaction between EndoS and IgM or IgA [24].
Furthermore, we could show here that EndoS(E235Q) does not
interact with IgG lacking its heavy chain glycans. This is in
contrast to both protein G and protein A that bind IgG
irrespective of its glycosylation state [24]. This could be especially
important when only intact IgG with a certain functional effector
region is required. When using currently available reagents like
protein G, a second purification step using for instance a lectin
column is required to obtain only the glycosylated fraction of IgG.
This property of EndoS(E235Q) could be used in combination
with for instance protein G to assess the glycosylation state and the
functional quality of an IgG preparation.
In conclusion, EndoS is a bacterial immunomodulatory protein
with a great potential. Our results provide novel information about
bacterial pathogenesis, i.e. how the pathogens evade the immune
system of the host organism by affecting the functions of IgG/
FccRs. Moreover, EndoS could be used as an important
biochemical tool for specific IgG N-glycan hydrolysis and IgG
purification/detection, or perhaps as a potential immunosuppress-
ing agent that could be used to interfere with antibody-mediated
pathological processes.
MATERIALS AND METHODS
Proteins and reagents
Blood was drawn from healthy individuals and collected in
heparin-containing tubes. Full-length EndoS with glutathione-S-
transferase (GST) as a fusion was recombinantly expressed and
purified from Escherichia coli harboring the plasmid pGEXndoS.
When appropriate, the GST-tag was removed using Factor Xa as
previously described [23]. The mutation of glutamic acid 235 of
EndoS into glutamine was performed using QuickChange II Site-
Directed Mutagenesis Kit according to manufacturer’s instructions
(Stratagene, La Jolla, CA) with following verification of the
mutation by sequencing [29]. Soluble purified Fc-receptors were
generated by co-transfection of CHO-K1(CHO) cells with pNT-
neo-FccRII or pNT-neo-FccRIII plasmids with subsequent
selection in 1 mg/ml genetecin [34]. IgG-subclasses were
produced by transient transfection in 293T cells [34]. RPMI
1640 medium and Hanks balanced salt solution (HBSS) were from
GIBCO, Paisley, U.K. All other reagents were purchased from
Sigma-Aldrich unless indicated otherwise.
EndoS-treatment of antibodies
Purified human IgG1–4 was hydrolyzed with GST-EndoS purified
as previously described [23]. Enzyme/substrate molar ratio was
1:20 in PBS and samples were incubated for 2 h at 37uC. GST-
EndoS was removed from the samples by passing three times over
a glutathione-Sepharose column (Amersham Biosciences, Uppsala,
Sweden). 1 mg of treated and untreated IgG1–4 was separated on
10% SDS-PAGE followed by staining with Coomassie Blue or Lens
culinaris agglutinin (LCA)-lectin (Vector Laboratories, Burlingame,
CA, USA) blot analysis (se below).
Treatment of human plasma with EndoS and
purification of IgG
A volume of 2 ml human plasma was incubated with 20 mg EndoS
or a PBS equivalent for 1.5 hours at 37uC. The IgG fraction was
purified using Protein G Sepharose (GE Healthcare Bio-sciences
AB, Uppsala, Sweden). Briefly, 200 ml Protein G Sepharose
suspended 1:1 in PBS (phosphate-buffered saline; 10 mM
phosphate buffer, pH 7.4, 120 mM NaCl, 3 mM KCl) was added
to plasma samples and incubated at 4uC for 2 hours or over night.
After centrifugation for five minutes at 80006g, the supernatant
was discarded and the pellet washed three times with PBS. IgG
was eluated with 0.1 M glycine pH 2.0 and neutralized with 1 M
Tris-HCl pH 8.0. The IgG concentration was determined to
8 mg/ml using the Advanced Protein Assay (Cytoskeleton,
Denver, CO, USA).
Cell preparations
The K562 cell line was cultured in RPMI 1640 medium
supplemented with Glutamax-I, 100 mg/ml antibiotics (penicillin
and streptomycin) and 10% fetal calf serum at 37uCi na n
atmosphere containing 5% CO2 and 95% humidity. Nunclon
flasks for cell culture were used (Nunc A/S, Roskilde, Denmark).
Cells were cultured in a serum free medium for 20 hours before
being used in experiments. Monocytes were isolated from human
whole blood using the Polymorphprep kit (AXIS-SHIELD, Oslo,
Norway) or Ficoll-Paque Plus (Amersham Biosciences, Uppsala,
Sweden) according to instructions provided by the manufacturers.
After isolation, the cells were counted and resuspended in PBS or
RPMI-medium.
Enzyme linked immunosorbent assay (ELISA)
For glycan detection, microtiter plates (NUNC, Roskilde, Den-
mark) were coated with 100 mL monoclonal mouse anti-human
IgG1, IgG2, IgG3 or IgG4 (SIGMAH, Saint Louis, MO, USA)
diluted to final concentrations of 1.5–0.5 mg/ml in a coating buffer
containing 16 mM Na2CO3 and 35 mM NaHCO3, pH 9.6 and
kept at 4uC overnight. The plates were washed three times with
lectin buffer containing 10 mM HEPES, pH 7.5, 0.15 M NaCl,
0.01 mM MnCl2, 0.1 mM CaCl2 and 0.1% v/v Tween 20 and
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the next step purified IgG fraction (dilution 1:100) was added and
the incubation proceeded for another 2 hours at 37uC. After three
washes with lectin buffer, 1 mg/ml biotinylated LCA-lectin was
added and incubation continued for 1 hour at 37uC. Following
three more washes, 0.1 mg/ml peroxidase-labeled streptavidin
(Vector Laboratories) was added and the plate was incubated for
1 hour at 37uC. The color reaction was developed with 0.1 M
citric acid monohydrate, 0.1 M Na2HPO462H2O buffer pH 4.5
containing 0.012% v/v H2O2 and 1.7 mM 2,29-azino-bis(3-
ethylbenzthiazoline-6-sulphonic acid) (ABTS). The absorbance
was read on a model 550 micro plate reader (BIO-RAD, Hercules,
CA, USA) at 415 nm. For detection of binding of human IgG
subclasses to FccRs, the plate was coated with soluble FccRIIa or
FccRIIb or FccRIIIa at a concentration 5 mg/ml for 20 hours at
4uC. Next day, the plate was blocked with PBS supplemented with
0.05% v/v Tween 20 (PBST) and 2% w/v bovine serum albumin
for 2 hours at room temperature. After this step, the purified IgG
subclasses, 0.1 mg of each, were added. The plate was washed
three times with PBST after the coating step and between each of
the following incubation steps. A peroxidase-conjugated protein G
(dilution 1:5000) (BIO-RAD, Hercules, CA, USA) was used for
detection. The color reaction was performed as above. All
experiments were made in triplicates.
Radioactive labeling
Proteins were labelled with 0.2 mCi Na
125I (PerkinElmer,
Upplands-Va ¨sby, Sweden) using the IODE-BEADS Iodination
reagent kit (PIERCE, Rockford, IL, USA) according to the
manufacturer’s instructions. The unbound radioactivity was
removed by desalting the proteins on PD-10 Sepharose (Pharma-
cia, Sweden). The activity of the labeled proteins was estimated to
4 mCi/mg protein.
Detection of IgG binding to cells
IgG was purified from human plasma treated with EndoS or PBS
as described above and thereafter labeled with
125iodine (
125I). For
detection of
125I-IgG binding to K562 cells, 2610
6 cells were
incubated with 0.5610
6 cpm of
125I-IgG or
125I-deglycosylated
IgG for 30 minutes at room temperature. After five washes with
PBS and centrifugations at 10006g for three minutes, the
radioactivity of the cell pellets was detected using Wallac
Wizard
TM 1470 Automatic Gamma Counter (PerkinElmer,
Waltham, MA, USA). To evaluate the specificity of the binding
of radioactive IgG to K562 cells a control experiment was
performed. The cells were incubated with 20 mg human IgG in
addition to radioactive IgG during the similar incubation
conditions as mentioned above. In another experiment, 1610
6
monocytes were incubated with 0.5610
6 cpm of
125I-IgG or
125I-
EndoS treated IgG for 30 minutes at room temperature. After five
repeated washes of cells with PBS and final pelleting of cells by
centrifugation at 10006g for five minutes, the cells were
resuspended in lysis buffer containing 20 mM Tris-HCl pH 7.4,
0.150 M NaCl, 1% v/v Triton-100 and 0.25% v/v NP40 for ten
minutes at 4uC. Next, the samples were centrifuged for ten
minutes at 140006g and supernatants applied on a polyacryl-
amide gel. After separation, the gel was dried and samples
analyzed by phosphoimaging in a Fujix BAS 2000 Bioimaging
analyzer (Fujifilm Sverige AB, Stockholm, Sweden). In an
experiment where the binding of IgG to cells was analyzed by
Western blot, 0.5–1610
6 cells were incubated with plasma treated
with either EndoS or buffer (as described above), at 37uC for
1 hour. Afterwards, the cells were washed three times with PBS or
RPMI medium, resuspended in 100 mL lysis buffer and the bound
IgG in cell lysates analyzed by Western blot.
Incubation of cells with EndoS
K562 cells or monocytes, 2610
6 and 8610
6 respectively, were
incubated with two ml of human plasma for 30 minutes at 37uC.
The cells were washed five times with PBS and centrifuged at
10006g for ten minutes after every wash. EndoS, 40 mg in PBS or
PBS alone was added to cells and incubation followed for one hour
at 37uC. Cells were washed three times with PBS and resuspended
in 100 mL lysis buffer. Samples were centrifuged for five minutes at
140006g, pellets discarded and supernatants analyzed for IgG and
glycan contents using SDS-PAGE and Western blot.
Slot-blotting analysis
IgG1–4, 0.3, 015 and 0.075 mg of each in PBS were applied to
PVDF membranes using a slot-blot apparatus from Schleicher and
Schuell, Inc., Kene, NH 03431, USA. The membranes were
incubated with PBST and 5% skim milk for 1 hour, washed with
PBST and incubated with EndoS or EndoS (E235Q), 0.05 mg/ml
in PBST and 5% skim milk for 1 hour. After washing, the
membranes were incubated with rabbit EndoS-antiserum and
subsequently with peroxidase conjugated goat anti-rabbit anti-
bodies. The color development was made using ABTS as
peroxidase substrate. All incubation steps were performed at
room temperature.
Surface plasmon resonance interaction analysis
Receptors, IgGs and deglycosylated IgGs were diluted with
10 mM sodium acetate pH 4 and immobilized via amine coupling
to different flow cells of CM5 sensorchips (BIAcore, Uppsala,
Sweden). Immobilization levels were optimized to around 8000–
10000 response units. After determining EndoS(E235Q) as a non-
binder to all deglycosylated IgG variants, these flow cells were
considered as controls for bulk refraction index changes for
EndoS(E235Q) binding to IgG1 throughout IgG4, respectively. In
experiments determining IgG1-IgG4 affinity for the receptors
FccRIIa, FccRIIb and FccRIIIa, a flow cell subjected to the
immobilization protocol but without addition of protein was used
as control. For affinity measurements, the binding and dissociation
phases were monitored in a BIAcore 2000 instrument. In control
experiments for possible mass transfer limitations, the IgGs were
injected over the receptors and the EndoS variants over the IgG
sub-classes at different flow rates. No differences in initial binding
were observed at 5 ml/min or above indicating no limitations to
any combinations. Interactants were injected in different concen-
trations (typically 10–1.25 mg/ml) at 35 ml/min and 25uC over the
different coated surfaces (flow cells) (in running buffer: 10 mM
HEPES, pH 7.5, 150 mM NaCl, 0.005% surfactant P20, and
3.4 mM EDTA). Between experiments, the surfaces were strictly
regenerated with pulses of running buffer containing 2 M NaCl
followed by an extensive wash procedure after reaching baseline.
For EndoS digestion of IgG bound to pre-immobilized FccRIIa,
an IgG1 concentration (10 mg/ml) was chosen to give a suitable
steady-state dissociation phase at a time point were the IgG1
injection was aborted and replaced by running buffer. This
experiment was considered as a control and as such compared to
an EndoS injection at the same time point after IgG1 binding to
FccRIIa. After X and Y normalization of data, the blank curves
from control flow cells of each injected concentration were
subtracted. Where applicable, the association (ka) and dissociation
(kd) rate constants were determined simultaneously using the
equation for 1:1 Langmuir binding in the BIA Evaluation 4.1
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equilibrium dissociation constants (KD) were calculated from mean
values of the obtained rate constants.
Flow cytometry analysis of whole blood
A volume of 15 ml blood was incubated with 0.4 mg EndoS or
PBS for 35 minutes at 37uC. An activator of leukocytes, formyl-
methionyl-leucyl-phenylalanine (fMLP), (dilution 1:10000) (SIG-
MA, Saint Louise, MO, USA) was then added and the incubation
continued for 10 minutes at 37uC. Next, blood samples were
centrifuged 10006g, five minutes. Plasma and buffy coat were
transferred to another tube and centrifuged for five minutes at
10006g. The cells were then washed three times with HBSS
containing 30% v/v RPMI and finally resuspended in 100 mlo f
the same medium. Monoclonal mouse anti-human IgG was
prepared by mixing equal amounts of mouse anti-human IgG1
(51 mg/ml), IgG2 (22 mg/ml), IgG3 (16 mg/ml) and IgG4
(24 mg/ml). Five ml of this mixture was added and samples
incubated for ten minutes at room temperature. In the next step
5 ml of FITC-conjugated goat anti-mouse IgG (DakoCytomation,
Glostrup, Denmark) was added before erythrocytes were lysed
using the DakoCytomation Uti-Lyse erythrocyte kit (Carpinteria,
CA). Signals were analyzed on a FACSCalibur flow cytometer
(Becton Dickinson, Franklin Lakes, NJ, USA). Monocytes were
identified by forward scatter and side scatter characteristics (FSC/
SSC).
SDS-PAGE and Western blot analysis
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) was performed using Mini Protean II cell equipment from
BIO-RAD (Hercules, CA, USA) or equipment from LKB
(Bromma, Sweden) using the buffer system described by Laemmli
[35]. Samples were mixed 1:1 (v/v) with sample buffer
supplemented with 5% mercaptoethanol, and boiled for five
minutes before loading onto the 10% polyacrylamide gel.
PageRuler
TM Protein Ladder Plus (Fermentas, Burlington,
Canada) was used as high-molecular-mass standards. The
polyacrylamide gels were stained with Coomassie Brilliant Blue
R-250 and in some cases dried. For immunoblotting, the gels were
transferred to polyvinylidenefluoride (PVDF) membranes (Immo-
bilon P, Millipore, Bedford, MA) as described by Matsudaira (18).
After blotting, membranes were blocked in PBS supplemented
with 0.05% v/v Tween 20 (PBST) and 5% w/v skim milk
(DIFCO, Detroit, MI) for 20 minutes at room temperature. For
detection of IgG, the blots were subsequently washed in PBST and
then incubated with rabbit anti-human IgG (diluted 1:3000) (BIO-
RAD, Hercules, CA) for one hour at 37uC. After a washing step,
membranes were incubated with horseradish peroxidase-conju-
gated goat anti-rabbit IgG (BIO-RAD) (dilution 1:1000). For lectin
blot analysis, membranes were blocked for 20 minutes in lectin
buffer (10 mM HEPES, pH 7.5, 0.15 M NaCl, 0.01 mM MnCl2,
0.1 mM CaCl2 and 0.1% v/v Tween 20) at room temperature and
incubated with biotinylated LCA lectin (diluted 1:5000). After
repeated washes in lectin buffer the membranes were incubated
with peroxidase-labeled streptavidin (Vector Laboratories) (diluted
1:10000). All membranes were developed using SuperSignal West
Pico (PIERCE, Rockford, IL) according to the manufacturer’s
instructions before analyzing by the Chemidoc XRS imaging
system and Quantity One image analysis software (BIO-RAD).
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